

A 2  
35. A composition comprising the inhibitor of claim 28 as an active ingredient and a pharmaceutically acceptable carrier.--

### Remarks

This amendment contains no new matter. Applicants have amended the specification to correct obvious typographical errors. In particular, Applicants have amended the specification on page 2, line 23 to insert the word "from" into the sentence. As addition of the word "from" serves only to make the sentence grammatically correct, it adds no new matter. Also, Applicants have amended the specification on page 8, line 31 to remove a stray and unnecessary typographic symbol. The specification on page 19, line 30 has been amended to replace the German word "ist" with its English equivalent "is". This amendment corrects an obvious typographic mistake which occurred during translation of the specification and adds no new matter. The specification has also been amended, on page 15, line 27 to correct the spelling of the word "complex." Further, the specification at page 32, line 21 has been amended to bring "50" and "g" in closer proximity to each other in order to clarify that what is being contemplated is 50 grams of protein per sample. This amendment corrects a formatting mistake and adds no new matter.

In view of the above, the amendments submitted herein do not add new matter and merely correct errors obvious to one skilled in the art. Accordingly, Applicants respectfully request that they be entered.

In addition, Applicants have canceled claims 1-16 without prejudice or disclaimer of the subject matter therein. New claims 17-35 have been added in order to more precisely define the invention, with claims 17 and 28 being the independent claims. The new claims are supported by the specification and original claims. Specifically, support for claims 17-18 can be found, *inter alia*, at page 17, lines 6-12 and page 20, lines 25-29. Support for claim 19 can be found, *inter alia*, at page 20, line 30 to page 23, line 2. Support for claims 20-22 can be found, *inter*

*alia*, at page 18, lines 19-27. Support for claim 23 can be found, *inter alia*, at page 30, line 30 to page 31, line 14. Support for claims 24-25 can be found, *inter alia*, at page 19, line 26 to page 20, line 12. Support for claims 26-27 can be found, *inter alia*, at page 20, line 30 to page 21, line 9. Support for claims 28-31 can be found, *inter alia*, at page 23, lines 3-11 and page 24, line 19 to page 15, line 12. Support for claim 32 can be found, *inter alia*, at page 25, lines 13-22. Support for claims 33-34 can be found, *inter alia*, at page 25, line 23 to page 26, line 7. Support for claim 35 can be found, *inter alia*, at page 23, lines 12-15 and lines 21-24; and page 25, lines 1-12.

It is not believed that extensions of time are required beyond those that may otherwise be provided for in accompanying documents. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor are hereby authorized to be charged to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Raz E. Fleshner  
Registration No. 34,331  
Attorney for Applicants

Date: August 3, 2001

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600